JP7791083B2 - カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法 - Google Patents

カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法

Info

Publication number
JP7791083B2
JP7791083B2 JP2022520291A JP2022520291A JP7791083B2 JP 7791083 B2 JP7791083 B2 JP 7791083B2 JP 2022520291 A JP2022520291 A JP 2022520291A JP 2022520291 A JP2022520291 A JP 2022520291A JP 7791083 B2 JP7791083 B2 JP 7791083B2
Authority
JP
Japan
Prior art keywords
salt
rilpivirine
cabotegravir
administered
intramuscular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550828A5 (https=
JP2022550828A (ja
JPWO2021064618A5 (https=
Inventor
ヘルタ、マリア、ルドビカ、クラウウェルズ
スーザン、エル．フォード
デイビッド、アンドリュー、マーゴリス
ステファーン、ルイ、エフ．ロセーヌ
ウィリアム、ロバート、スプリーン
ロディカ、ミハエラ、ファン、ゾーリンゲン－リステア
ピーター、エバン、オーウェン、ウィリアムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare Co
Original Assignee
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare Co filed Critical ViiV Healthcare Co
Publication of JP2022550828A publication Critical patent/JP2022550828A/ja
Publication of JP2022550828A5 publication Critical patent/JP2022550828A5/ja
Publication of JPWO2021064618A5 publication Critical patent/JPWO2021064618A5/ja
Application granted granted Critical
Publication of JP7791083B2 publication Critical patent/JP7791083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022520291A 2019-10-01 2020-10-01 カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法 Active JP7791083B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908882P 2019-10-01 2019-10-01
US201962908995P 2019-10-01 2019-10-01
US62/908,995 2019-10-01
US62/908,882 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US63/037,782 2020-06-11
US202063052214P 2020-07-15 2020-07-15
US63/052,214 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Publications (4)

Publication Number Publication Date
JP2022550828A JP2022550828A (ja) 2022-12-05
JP2022550828A5 JP2022550828A5 (https=) 2023-10-12
JPWO2021064618A5 JPWO2021064618A5 (https=) 2023-10-12
JP7791083B2 true JP7791083B2 (ja) 2025-12-23

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520291A Active JP7791083B2 (ja) 2019-10-01 2020-10-01 カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法

Country Status (11)

Country Link
US (3) US20220347174A1 (https=)
EP (1) EP4037661A1 (https=)
JP (1) JP7791083B2 (https=)
KR (1) KR20220074880A (https=)
CN (2) CN118416069A (https=)
AU (1) AU2020358156B2 (https=)
CA (1) CA3155587A1 (https=)
CL (1) CL2022000790A1 (https=)
IL (1) IL290716A (https=)
MX (1) MX2022003945A (https=)
WO (1) WO2021064618A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
WO2023222754A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016732A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2480220T3 (pl) * 2009-09-22 2015-10-30 Janssen Sciences Ireland Uc Leczenie i zapobieganie zakażeniu HIV
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
LT3986561T (lt) * 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016732A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed，2019年01月，インターネット＜URL：https://cdn.clinicaltrials.gov/large-docs/52/NCT02951052/Prot_000.pdf＞
Clinical Pharmacology in Drug Development，2019年2月, Vol.8, No.5，pp.664-673
Current Opinion in HIV and AIDS，2013年, Vol.8, No.6，pp.565-571
HIV/AIDS - Research and Palliative Care，2019年7月, Vol.2019, No.11，pp.179-192
Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy，2019年02月，インターネット＜URL：https://www.croiconference.org/wp-content/uploads/sites/2/posters/2017/442_Margolis.pdf＞
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine FromCurrent Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults，2019年07月，インターネット＜URL：https://clinicaltrials.gov/study/NCT02951052?term=NCT02951052&rank=1&tab=history&a=52＞
The LANCET，2017年，Vol.390，p.1499-1510

Also Published As

Publication number Publication date
US20250302830A1 (en) 2025-10-02
AU2020358156B2 (en) 2024-06-06
IL290716A (en) 2022-04-01
CA3155587A1 (en) 2021-04-08
WO2021064618A1 (en) 2021-04-08
EP4037661A1 (en) 2022-08-10
KR20220074880A (ko) 2022-06-03
CN118416069A (zh) 2024-08-02
US20250302829A1 (en) 2025-10-02
CN114502166A (zh) 2022-05-13
JP2022550828A (ja) 2022-12-05
CL2022000790A1 (es) 2022-11-25
AU2020358156A1 (en) 2022-04-21
US20220347174A1 (en) 2022-11-03
MX2022003945A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
Deeks Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection: ED Deeks
US20250302830A1 (en) Method for treating hiv with cabotegravir and rilpivirine
US11123329B1 (en) Use of angiotensin II type 2 receptor agonist
JP2025111701A (ja) 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド
Tseng et al. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs
JP2023123523A (ja) Ｈｉｖの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物
Yu et al. Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update
TWI879737B (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Raines et al. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
Koren et al. Scientific basis of antiretroviral therapy
Johnson et al. A systematic review of the use of atazanavir in women infected with HIV-1
JP2025001026A (ja) ドルテグラビル及びラミブジンでｈｉｖを治療する方法
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
Vanangamudi et al. Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy
JP2020528413A (ja) Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
Ballon New drugs
AU2024318637A1 (en) Obefazimod for treatment of ulcerative colitis
Pett et al. Atazanavir
Flamm Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting
Blonk et al. and David M. Burger
Benzer et al. The current state of HIV therapy.
Tablets FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251211

R150 Certificate of patent or registration of utility model

Ref document number: 7791083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150